At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 432 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Ruxolitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib and Placebo for Cytokine Storm (Covid-19). Completed, enrolled 432 participants across 61 sites in 12 countries.
Detailed Summary
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytokine Storm (Covid-19)
CountriesArgentina, Brazil, Colombia, France, Germany, Mexico, Peru, Russia, Spain, Turkey (Türkiye), United Kingdom, United States
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartMay 2, 2020
Primary CompletionOct 17, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.2 years ago
Interventions
Ruxolitinibdrug
Ruxolitinib 5 mg tablets
Placebodrug
Matching-image placebo